Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis.

The differential diagnosis of inflammatory arthritis as an immune-related adverse event can be challenging as patients with cancer can present with musculoskeletal symptoms that can mimic arthritis because of localized or generalized joint pain. In addition, immune checkpoint inhibitors can exacerbate joint conditions such as crystal-induced arthritis or osteoarthritis, or induce systemic disease that can affect the joints such as sarcoidosis. This distinction is important as the treatment of these conditions can be different from that of immune-related inflammatory arthritis.

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors declare no conflict of interest related with the preparation or content of the current article. J.A. Gómez-Puerta has received consulting fees from Abbvie, Astra Zeneca, Galápagos, GSK; Eli Lilly, Pfizer, and Otsuka unrelated to this work. K. Gente has received a research grant from the Medical Faculty of Heidelberg University, National Center for Tumor Diseases (NCT) Heidelberg, Rheuma-Liga Baden-Württemberg e.V. and Novartis, and consulting fees from BMS, Gilead/Galapagos, Hexal and Janssen unrelated to this work. M.E. Suarez-Almazor has received consulting fees from Pfizer, Eli Lilly, Celgene, and Syneos Health unrelated to this work. T.R. Katsumoto has received a research grant from Sanofi, United States, and consulting fees from Genentech and Sonoma Biotherapeutics unrelated to this work. P. Reid has a patent pending regarding the use of interleukin 6 axis inhibitors for viral infection–associated pneumonitis.